HURA TuHURA Biosciences | $2.47
+10.8% | 6/23/2025 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | High | View details for Brookline Capital Management rating of TuHURA Biosciences (NASDAQ:HURA) on 6/23/2025 |
BIVI BioVie | $0.93
+0.6% | 3/18/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of BioVie (NASDAQ:BIVI) on 3/18/2025 |
CRVO CervoMed | $5.93
-5.6% | 3/11/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Hold -> Strong-Buy | | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 3/11/2025 |
CATX Perspective Therapeutics | $3.28
-4.7% | 3/10/2025 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | Low | View details for Brookline Capital Management rating of Perspective Therapeutics (NYSE:CATX) on 3/10/2025 |
IMAB I-Mab | $2.34
-3.3% | 2/27/2025 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of I-Mab (NASDAQ:IMAB) on 2/27/2025 |
MRKR Marker Therapeutics | $1.51
-1.3% | 2/10/2025 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Strong-Buy | | Medium | View details for Brookline Capital Management rating of Marker Therapeutics (NASDAQ:MRKR) on 2/10/2025 |
CGTX Cognition Therapeutics | $0.31
+0.8% | 1/27/2025 | Upgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy | | High | View details for Brookline Capital Management rating of Cognition Therapeutics (NASDAQ:CGTX) on 1/27/2025 |
MDCX Medicus Pharma | $2.95
-1.3% | 12/23/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Medicus Pharma (NASDAQ:MDCX) on 12/23/2024 |
EXEL Exelixis | $43.62
-1.0% | 12/23/2024 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | | N/A | View details for Brookline Capital Management rating of Exelixis (NASDAQ:EXEL) on 12/23/2024 |
QNCX Quince Therapeutics | $1.52
-7.9% | 12/18/2024 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $9.00 | N/A | View details for Brookline Capital Management rating of Quince Therapeutics (NASDAQ:QNCX) on 12/18/2024 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
CRVO CervoMed | $5.93
-5.6% | 12/10/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Strong-Buy -> Hold | | N/A | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 12/10/2024 |
YMAB Y-mAbs Therapeutics | $4.41
-2.2% | 12/4/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Strong-Buy | | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/4/2024 |
YMAB Y-mAbs Therapeutics | $4.41
-2.2% | 12/5/2024 | Initiated by | Brookline Capital Management | - | Buy | $17.00 | N/A | View details for Brookline Capital Management rating of Y-mAbs Therapeutics (NASDAQ:YMAB) on 12/5/2024 |
EYEN Eyenovia | $10.56
+1.7% | 11/15/2024 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 11/15/2024 |
COCH Envoy Medical | $1.49
+4.9% | 10/14/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $9.00 | Low | View details for Brookline Capital Management rating of Envoy Medical (NASDAQ:COCH) on 10/14/2024 |
VRCA Verrica Pharmaceuticals | $0.60
+13.4% | 10/2/2024 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | High | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 10/2/2024 |
OSTX OS Therapies | $1.93
+2.7% | 8/22/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of OS Therapies (NYSE:OSTX) on 8/22/2024 |
IBIO iBio | $0.75
-1.7% | 7/22/2024 | Initiated by | Brookline Capital Management | Analyst K. Dolliver | Buy | $3.60 | Low | View details for Brookline Capital Management rating of iBio (NYSE:IBIO) on 7/22/2024 |
UNCY Unicycive Therapeutics | $4.90
+2.7% | 7/9/2024 | Upgraded by | Brookline Capital Management | Analyst K. Raja | Strong-Buy | | Low | View details for Brookline Capital Management rating of Unicycive Therapeutics (NASDAQ:UNCY) on 7/9/2024 |
CRVO CervoMed | $5.93
-5.6% | 7/8/2024 | Initiated by | Brookline Capital Management | Analyst T. Bussian | Buy | $63.00 | Low | View details for Brookline Capital Management rating of CervoMed (NASDAQ:CRVO) on 7/8/2024 |
SABS SAB Biotherapeutics | $1.76
+0.3% | 6/7/2024 | Initiated by | Brookline Capital Management | - | Buy | $8.00 | Low | View details for Brookline Capital Management rating of SAB Biotherapeutics (NASDAQ:SABS) on 6/7/2024 |
FBRX Forte Biosciences | $12.44
-3.8% | 5/30/2024 | Initiated by | Brookline Capital Management | - | Buy | $4.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 5/30/2024 |
DARE Dare Bioscience | $2.37
-0.8% | 5/15/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $36.00 | Low | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 5/15/2024 |
DARE Dare Bioscience | $2.37
-0.8% | 4/17/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | N/A | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/17/2024 |
IMUX Immunic | $0.69
-1.0% | 4/5/2024 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $10.00 | Low | View details for Brookline Capital Management rating of Immunic (NASDAQ:IMUX) on 4/5/2024 |
ATBPF Antibe Therapeutics | $0.22
| 3/4/2024 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 3/4/2024 |
ANVS Annovis Bio | $2.34
+7.8% | 2/28/2024 | Downgraded by | Brookline Capital Management | Analyst T. Bussian | Buy -> Hold | $9.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 2/28/2024 |
OTLK Oncobiologics | $1.58
-1.3% | 1/25/2024 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | $31.40 | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 1/25/2024 |
LNTH Lantheus | $79.42
-3.0% | 11/30/2023 | Initiated by | Brookline Capital Management | - | Buy | $100.00 | Low | View details for Brookline Capital Management rating of Lantheus (NASDAQ:LNTH) on 11/30/2023 |
ANVS Annovis Bio | $2.34
+7.8% | 11/10/2023 | Reiterated by | Brookline Capital Management | Analyst T. Bussian | Buy | $35.00 | Low | View details for Brookline Capital Management rating of Annovis Bio (NYSE:ANVS) on 11/10/2023 |
GNLX Genelux | $2.83
-1.4% | 10/30/2023 | Upgraded by | Brookline Capital Management | Analyst K. Dolliver | Hold -> Buy | | Low | View details for Brookline Capital Management rating of Genelux (NASDAQ:GNLX) on 10/30/2023 |
EYEN Eyenovia | $10.56
+1.7% | 10/17/2023 | Initiated by | Brookline Capital Management | - | Buy | $640.00 | Low | View details for Brookline Capital Management rating of Eyenovia (NASDAQ:EYEN) on 10/17/2023 |
EDSA Edesa Biotech | $2.03
| 10/12/2023 | Reiterated by | Brookline Capital Management | - | Buy -> Buy | $57.00 | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/12/2023 |
PROC Procaps Group | $0.95
-40.3% | 9/6/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | $4.50 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 9/6/2023 |
OTLK Oncobiologics | $1.58
-1.3% | 8/30/2023 | Downgraded by | Brookline Capital Management | Analyst K. Dolliver | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 8/30/2023 |
ATBPF Antibe Therapeutics | $0.22
| 8/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 8/14/2023 |
DARE Dare Bioscience | $2.37
-0.8% | 2/14/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 2/14/2023 |
ECOR electroCore | $5.24
-0.8% | 1/12/2023 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 1/12/2023 |
IMNN Imunon | $0.78
-2.4% | 11/14/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 11/14/2022 |
VXRT Vaxart | $0.46
+1.7% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 10/3/2022 |
Forget Nvidia, This “Ghost Town” Company Holds the Key to the AI Boom (Ad) Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. Click here to see the details on what could be the biggest tech story of this decade. |
OTLK Oncobiologics | $1.58
-1.3% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 10/3/2022 |
MNPR Monopar Therapeutics | $33.56
-6.2% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 10/3/2022 |
LSTA Lisata Therapeutics | $2.86
-1.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Lisata Therapeutics (NASDAQ:LSTA) on 10/3/2022 |
IMNN Imunon | $0.78
-2.4% | 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Imunon (NASDAQ:IMNN) on 10/3/2022 |
EDSA Edesa Biotech | $2.03
| 10/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 10/3/2022 |
ARCT Arcturus Therapeutics | $12.99
-0.2% | 8/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/10/2022 |
ATBPF Antibe Therapeutics | $0.22
| 6/30/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/30/2022 |
VERU Veru | $0.59
+1.4% | 5/18/2022 | Target Raised by | Brookline Capital Management | Analyst Kumaraguru Raja | Buy -> Buy | $29.00 -> $31.00 | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 5/18/2022 |
VRCA Verrica Pharmaceuticals | $0.60
+13.4% | 3/10/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Verrica Pharmaceuticals (NASDAQ:VRCA) on 3/10/2022 |
NTLA Intellia Therapeutics | $9.88
+5.3% | 3/7/2022 | Upgraded by | Brookline Capital Management | Analyst L. Cann | Hold -> Buy | $91.00 | High | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 3/7/2022 |
CRSP CRISPR Therapeutics | $48.51
-0.3% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | $143.00 | High | View details for Brookline Capital Management rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/14/2022 |
NTLA Intellia Therapeutics | $9.88
+5.3% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst Leah Rush | Buy | | Low | View details for Brookline Capital Management rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/14/2022 |
CRBU Caribou Biosciences | $1.25
-0.8% | 2/14/2022 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Medium | View details for Brookline Capital Management rating of Caribou Biosciences (NASDAQ:CRBU) on 2/14/2022 |
BCDA BioCardia | $2.00
+2.6% | 2/3/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 2/3/2022 |
ICCM IceCure Medical | $1.02
+2.5% | 2/1/2022 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Low | View details for Brookline Capital Management rating of IceCure Medical (NASDAQ:ICCM) on 2/1/2022 |
DARE Dare Bioscience | $2.37
-0.8% | 1/19/2022 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 1/19/2022 |
PROC Procaps Group | $0.95
-40.3% | 12/14/2021 | Reiterated by | Brookline Capital Management | Analyst Kemp Dolliver | Buy | $13.00 | Low | View details for Brookline Capital Management rating of Procaps Group (NASDAQ:PROC) on 12/14/2021 |
KYMR Kymera Therapeutics | $44.44
+1.8% | 10/13/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | $80.00 | Medium | View details for Brookline Capital Management rating of Kymera Therapeutics (NASDAQ:KYMR) on 10/13/2021 |
FBRX Forte Biosciences | $12.44
-3.8% | 9/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Hold | | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 9/3/2021 |
VERU Veru | $0.59
+1.4% | 8/27/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/27/2021 |
SCYX SCYNEXIS | $0.70
+3.9% | 8/24/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/24/2021 |
CCCC C4 Therapeutics | $1.51
+5.6% | 6/25/2021 | Reiterated by | Brookline Capital Management | Analyst Leah Rush Cann | Buy | | High | View details for Brookline Capital Management rating of C4 Therapeutics (NASDAQ:CCCC) on 6/25/2021 |
ATBPF Antibe Therapeutics | $0.22
| 6/3/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | Medium | View details for Brookline Capital Management rating of Antibe Therapeutics (OTCMKTS:ATBPF) on 6/3/2021 |
MNPR Monopar Therapeutics | $33.56
-6.2% | 5/25/2021 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Medium | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 5/25/2021 |
BIOX Bioceres Crop Solutions | $4.59
+2.7% | 5/7/2021 | Reiterated by | Brookline Capital Management | Analyst K. Dolliver | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 5/7/2021 |
NLSP NLS Pharmaceutics | $2.86
-1.4% | 3/12/2021 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of NLS Pharmaceutics (NASDAQ:NLSP) on 3/12/2021 |
MRNA Moderna | $28.69
+4.0% | 2/26/2021 | Target Raised by | Brookline Capital Management | - | Buy | $180.00 -> $205.00 | Low | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 2/26/2021 |
XFOR X4 Pharmaceuticals | $1.86
-2.1% | 12/17/2020 | Initiated by | Brookline Capital Management | Analyst L. Cann | Buy | $630.00 | High | View details for Brookline Capital Management rating of X4 Pharmaceuticals (NASDAQ:XFOR) on 12/17/2020 |
VERU Veru | $0.59
+1.4% | 12/14/2020 | Target Raised by | Brookline Capital Management | Analyst K. Raja | | $13.00 -> $17.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 12/14/2020 |
ECOR electroCore | $5.24
-0.8% | 10/23/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $75.00 | Low | View details for Brookline Capital Management rating of electroCore (NASDAQ:ECOR) on 10/23/2020 |
FBRX Forte Biosciences | $12.44
-3.8% | 8/28/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $90.00 | Low | View details for Brookline Capital Management rating of Forte Biosciences (NASDAQ:FBRX) on 8/28/2020 |
KURA Kura Oncology | $5.60
-2.9% | 8/16/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | | Low | View details for Brookline Capital Management rating of Kura Oncology (NASDAQ:KURA) on 8/16/2020 |
VERU Veru | $0.59
+1.4% | 8/14/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 8/14/2020 |
ARCT Arcturus Therapeutics | $12.99
-0.2% | 8/11/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 8/11/2020 |
MRNA Moderna | $28.69
+4.0% | 7/13/2020 | Reiterated by | Brookline Capital Management | Analyst L. Cann | Buy | $95.00 | High | View details for Brookline Capital Management rating of Moderna (NASDAQ:MRNA) on 7/13/2020 |
ASRT Assertio | $0.64
+0.1% | 6/3/2020 | Initiated by | Brookline Capital Management | - | Buy | $3.50 | Low | View details for Brookline Capital Management rating of Assertio (NASDAQ:ASRT) on 6/3/2020 |
OTLK Oncobiologics | $1.58
-1.3% | 5/5/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Oncobiologics (NASDAQ:OTLK) on 5/5/2020 |
DARE Dare Bioscience | $2.37
-0.8% | 4/28/2020 | Initiated by | Brookline Capital Management | Analyst S. Yanchus | Buy | $90.00 | High | View details for Brookline Capital Management rating of Dare Bioscience (NASDAQ:DARE) on 4/28/2020 |
EDSA Edesa Biotech | $2.03
| 3/30/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $70.00 | High | View details for Brookline Capital Management rating of Edesa Biotech (NASDAQ:EDSA) on 3/30/2020 |
CLPT ClearPoint Neuro | $11.26
-5.7% | 3/11/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | High | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/11/2020 |
ARMP Armata Pharmaceuticals | $1.89
-0.5% | 3/13/2020 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) on 3/13/2020 |
CLPT ClearPoint Neuro | $11.26
-5.7% | 3/12/2020 | Initiated by | Brookline Capital Management | - | Buy | $15.00 | N/A | View details for Brookline Capital Management rating of ClearPoint Neuro (NASDAQ:CLPT) on 3/12/2020 |
MNPR Monopar Therapeutics | $33.56
-6.2% | 2/19/2020 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $210.00 | High | View details for Brookline Capital Management rating of Monopar Therapeutics (NASDAQ:MNPR) on 2/19/2020 |
BIOX Bioceres Crop Solutions | $4.59
+2.7% | 2/4/2020 | Reiterated by | Brookline Capital Management | Analyst S. Yanchus | Buy | | N/A | View details for Brookline Capital Management rating of Bioceres Crop Solutions (NASDAQ:BIOX) on 2/4/2020 |
BCDA BioCardia | $2.00
+2.6% | 11/26/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
BCDA BioCardia | $2.00
+2.6% | 11/26/2019 | Initiated by | Brookline Capital Management | - | Buy | $330.00 | Low | View details for Brookline Capital Management rating of BioCardia (NASDAQ:BCDA) on 11/26/2019 |
MDNA Medicenna Therapeutics | C$0.85
+2.4% | 11/19/2019 | Reiterated by | Brookline Capital Management | - | Buy | C$4.00 | N/A | View details for Brookline Capital Management rating of Medicenna Therapeutics (TSE:MDNA) on 11/19/2019 |
SCYX SCYNEXIS | $0.70
+3.9% | 8/19/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 8/19/2019 |
VXRT Vaxart | $0.46
+1.7% | 8/15/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $6.00 | Low | View details for Brookline Capital Management rating of Vaxart (NASDAQ:VXRT) on 8/15/2019 |
VERU Veru | $0.59
+1.4% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $12.00 | High | View details for Brookline Capital Management rating of Veru (NASDAQ:VERU) on 7/29/2019 |
This Signal Only Flashes Once Every 4 Years – And It Just Triggered (Ad) This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto.
Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave. Missed the Last Crypto Boom? Don’t Miss This One - PLUS Claim your $10 in Bitcoin |
CLRB Cellectar Biosciences | $4.86
-31.6% | 7/29/2019 | Initiated by | Brookline Capital Management | Analyst K. Raja | Buy | $1,800.00 -> $1,800.00 | High | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 7/29/2019 |
ARCT Arcturus Therapeutics | $12.99
-0.2% | 7/24/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 7/24/2019 |
SCYX SCYNEXIS | $0.70
+3.9% | 1/4/2019 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | High | View details for Brookline Capital Management rating of SCYNEXIS (NASDAQ:SCYX) on 1/4/2019 |
CLRB Cellectar Biosciences | $4.86
-31.6% | 11/20/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Cellectar Biosciences (NASDAQ:CLRB) on 11/20/2018 |
ARCT Arcturus Therapeutics | $12.99
-0.2% | 9/27/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Arcturus Therapeutics (NASDAQ:ARCT) on 9/27/2018 |
TNXP Tonix Pharmaceuticals | $37.30
+3.7% | 7/27/2018 | Downgraded by | Brookline Capital Management | Analyst K. Raja | Buy -> Hold | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 7/27/2018 |
TNXP Tonix Pharmaceuticals | $37.30
+3.7% | 5/1/2018 | Reiterated by | Brookline Capital Management | Analyst K. Raja | Buy | | Low | View details for Brookline Capital Management rating of Tonix Pharmaceuticals (NASDAQ:TNXP) on 5/1/2018 |
